Salesforce Shares (CRM) Gain 4.2% After JPMorgan Sets $250 Goal, Putting a 4.7-Point Rule-of-50 Gap in Focus

Salesforce Shares (CRM) Gain 4.2% After JPMorgan Sets $250 Goal, Putting a 4.7-Point Rule-of-50 Gap in Focus

···
14 August 2026
Shares of Salesforce, Inc. rose 4.16% on Thursday as JPMorgan reiterated an overweight rating and set a $250 price target for the software company. The stock ended regular trading at $201.37 before slipping 0.44% to $200.48 after the bell. The rally during the regular session increased Salesforce’s market capitalization by about $6.6 billion.
Read More: Salesforce Shares (CRM) Gain 4.2% After JPMorgan Sets $250 Goal, Putting a 4.7-Point Rule-of-50 Gap in Focus

Workday Shares Surge 20% After Silver Lake Negotiations Boost Deal Value by $8.6 Billion

Workday Shares Surge 20% After Silver Lake Negotiations Boost Deal Value by $8.6 Billion

···
13 August 2026
Shares of Workday finished Thursday at $210.19, gaining $34.90, or 19.9%, compared to Wednesday’s close following a Reuters report that Silver Lake was discussing an acquisition of the enterprise-software maker. The share price reached an intraday peak of $227.49.
Read More: Workday Shares Surge 20% After Silver Lake Negotiations Boost Deal Value by $8.6 Billion
Nvidia Stock (NVDA) Gains 3% in Premarket Amid Analyst Target $563 Below Current Level—Potential Caution Flag

Nvidia Stock (NVDA) Gains 3% in Premarket Amid Analyst Target $563 Below Current Level—Potential Caution Flag

····
13 August 2026
NVIDIA rose 3.03% on Wednesday, driven by a recovery in AI infrastructure stocks. However, broader investor focus remains on Wall Street's outlook. Analyst price targets now stretch from $180 to $743, with consensus positioned at approximately $314.
Read More: Nvidia Stock (NVDA) Gains 3% in Premarket Amid Analyst Target $563 Below Current Level—Potential Caution Flag

Latest

Moderna Secures U.S. mRNA Flu Vaccine Approval, Revenue Gains Not Expected Before 2027

Moderna Secures U.S. mRNA Flu Vaccine Approval, Revenue Gains Not Expected Before 2027

CAMBRIDGE, Massachusetts, August 14, 2026, 10:53 EDT — Moderna Inc. secured regulatory clearance for its pioneering mRNA-based flu vaccine in the United States, but analysts expect the new product will not make a significant impact on revenue until late 2027, positioning the breakthrough as a challenge for the company’s cash management.
····
14 Aug
Nvidia Stock Encounters $125 Billion Floor as Wall Street Pursues $500 Billion AI Ambition

Nvidia Stock Encounters $125 Billion Floor as Wall Street Pursues $500 Billion AI Ambition

NVIDIA Corporation shares climbed slightly in early trade Friday as a new financing disclosure shifted focus to the company’s balance-sheet exposure rather than chip market demand. The stock settled at $225.30 on Thursday, after reaching $227.23 during the session. NVIDIA was listed among the most actively traded U.S. stocks on Yahoo Finance.
···
14 Aug